NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, Forecast & News

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) issued its quarterly earnings data on Monday, November, 4th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by $0.09. View Deciphera Pharmaceuticals' Earnings History.

Deciphera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Deciphera Pharmaceuticals.

13 Wall Street analysts have issued 12 month price objectives for Deciphera Pharmaceuticals' shares. Their forecasts range from $29.00 to $84.00. On average, they anticipate Deciphera Pharmaceuticals' stock price to reach $62.23 in the next twelve months. This suggests that the stock has a possible downside of 4.8%. View Analyst Price Targets for Deciphera Pharmaceuticals.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals.

News headlines about DCPH stock have trended extremely negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Deciphera Pharmaceuticals earned a news impact score of -5.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,500,000 shares, an increase of 7.8% from the December 15th total of 2,320,000 shares. Based on an average daily volume of 544,200 shares, the days-to-cover ratio is currently 4.6 days. Currently, 8.0% of the shares of the company are sold short. View Deciphera Pharmaceuticals' Current Options Chain.

Some companies that are related to Deciphera Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Fate Therapeutics (FATE), Global Blood Therapeutics (GBT), Iovance Biotherapeutics (IOVA), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Crispr Therapeutics (CRSP).

(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.07%), Strs Ohio (0.03%) and SG Americas Securities LLC (0.01%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly. View Institutional Ownership Trends for Deciphera Pharmaceuticals.

DCPH stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly. View Insider Buying and Selling for Deciphera Pharmaceuticals.

DCPH stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and SG Americas Securities LLC. View Insider Buying and Selling for Deciphera Pharmaceuticals.

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DCPH stock can currently be purchased for approximately $65.40.

Deciphera Pharmaceuticals has a market capitalization of $3.34 billion. The company earns $-99,850,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.View Additional Information About Deciphera Pharmaceuticals.

The official website for Deciphera Pharmaceuticals is http://www.deciphera.com/.

Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]